Morning folks,
Whilst we await updates from the company on our own clinical trials, thought I would share the following which was presented at AACR23 on another Oncolytic virus trial - also an adenovirus as outlined in one of the examples provided by @Outlander2 above.
What I liked about this post is that these guys provided a small video to talk through the poster presentation and it provides a good overview of the trial and some early observations.
You can draw your own conclusions of course, but there are some obvious parallels to our own CF33 trial.
The tweet for the Moffitt Cancer Centre includes a link for the abstract of the poster presentation shown in the clip.
Moffitt Cancer Center on Twitter: "While at #AACR23, we met up with Dr. Andreas N. Saltos to discuss a phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity. Read more ➡️ https://t.co/NBTcnXUIis @AACR https://t.co/3j8hcCdfqH" / Twitter
Looking forward to updates on CF33!
GLTAH.
Competitive landscape, page-197
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
-0.001(1.96%) |
Mkt cap ! $367.4M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.2¢ | 4.9¢ | $896.1K | 17.89M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 5978561 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 299041 | 4 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |